Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes

Journal of the American College of Cardiology

Volumn 52, Issue 22, 2008, Pages 1758-1768

  Pinto, Duane S ^a,h   Stone, Gregg W ^b   Shi, Chunxue ^h,i   Dunn, Elizabeth S ^h   Reynolds, Matthew R ^a,h   York, Meghan ^a   Walczak, Joshua ^h   Berezin, Ronna H ^h   Mehran, Roxana ^b   McLaurin, Brent T ^d   Cox, David A ^e   Ohman, E Magnus ^f   Lincoff, A Michael ^c   Cohen, David J ^g,h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ANMED HEALTH   (United States)

^e LEHIGH VALLEY HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^h HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ I3 Statprobe/UHG   (United States)

Author keywords

direct thrombin inhibition; economic analysis; non ST segment myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; HIRULOG; TIROFIBAN;

ACCOUNTING; ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART CATHETERIZATION; HIGH RISK POPULATION; HOSPITAL BILLING; HOSPITAL CHARGE; HUMAN; ISCHEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 56049084491     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.08.021     Document Type: Article

References (12)

1. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
2. Stone G.W., Bertrand M., Colombo A., et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148 (2004) 764-775
3. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) e1-e157
4. Cohen D.J., Krumholz H.M., Sukin C.A., et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial. Circulation 92 (1995) 2480-2487
5. Taira D.A., Seto T.B., Siegrist R., Cosgrove R., Berezin R., and Cohen D.J. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J 145 (2003) 452-458
6. Shwartz M., Young D.W., and Siegrist R. The ratio of costs to charges: how good a basis for estimating costs?. Inquiry 32 (1995) 476-481
7. Efron B., and Tibshirani R.J. An Introduction to the Bootstrap (1993), Chapman & Hall, New York, NY
8. Stone G.W., Ware J.H., Bertrand M.E., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298 (2007) 2497-2506
9. Mark D.B., Harrington R.A., Lincoff A.M., et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 101 (2000) 366-371
10. Glaser R., Glick H.A., Herrmann H.C., and Kimmel S.E. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. J Am Coll Cardiol 47 (2006) 529-537
11. Cohen D.J., Lincoff A.M., Lavelle T.A., et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800
12. Stone G.W., Bertrand M.E., Moses J.W., et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing Trial. JAMA 297 (2007) 591-602